维普中文期刊产品整合服务
16篇 您的检索式:作者名="Sahz L"
    题名 作者 年代 出处 被引量
1The presence and intensity of the cetuximab - induced ache - like rash predicts increased survival in studies across multiple malignancies 显示文摘Sahz L Kies M Abbruzzese J 2003Proc Am Clin Oncol2003,22,:1
2Methylight:a high-throughput assay to meas ure DNA methylation显示文摘Eads C A Danenberg K D Kawakami K Sahz L B Blake C Shibata D 2000Nucleic Acids Res2000,28,:1
3Bevacizumab (Bey) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/No16966, a randomized phase Ⅲ trial in first-line metastatic colorectal cancer显示文摘Sahz L Clarke S Diaz-Rubio E 2007J Clin Oncol2007,25,18:1
4The presence and intensity of the cetuximab-induced acne-like rash predicts in- creased survival in studies across multiple malignancies r 显示文摘Sahz L B Kies M S Abbruzzese J L 2003Proc Am Soc Clin Oncol2003,22,20:1
5lrinotecan plus fluorour~icil and leucovorin for metastatic colorectal cancer显示文摘Sahz L B Cox J V Blanke C 2000New England Journal of Medicine2000,343,13:1
6Adjuvant therapy for colorectal cancer显示文摘Cohen AM Kelsen D Sahz L 1997Curr Probl Surg1997,34,8:1
7Managing chemotherapy -induced diarrhea 显示文摘Sahz L B 2006Clin Adv Hematol Oncol2006,4,3:1
8Adjuvant therapy for colorectal cancer显示文摘Cohen AM Kelsen D Sahz L 1997Curr Probl Surg1997,34,8:1
9Safety profile of cetuximab in patients with metastatic colorectal cancer 显示文摘Gustafson NF Sahz L Cunningham D 2004Gastroiptestinal Cancers Symposium2004,,:1
10Antibody-based therapies for colorect cancer 显示文摘Chung K Y Sahz L B 2005Oncologist2005,10,9:1
11Phase Ⅱ trail of cetuximab in patientswith refractory colorectal cancer ex press the epidermal growth factor recepter显示文摘Sahz L B Meropol N J Loehree P J 2004J Clin Oncol2004,22,7:1
12Cutaneous adverse effects with HER1/EGFR-targetad agents: is there a silver lining? 显示文摘Perez-Soler R Sahz L 2005J Clin Oncol2005,23,22:1
13FAMTX venus etoposide doxontbicin and cisp|atin: a randomized trial in gastric cancert显示文摘Kelsen D Atiq OT Sahz L 1992J Clin Oncol1992,10,2:1
14Randomized phaselI trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuxima/ bevacizumab (CB) in irinotecan-refractory colorectal cancer (abst) 显示文摘Sahz L Lenz H KindlerHL 2007J Clin Oncol2007,25,29:1
15FAMTX versus etoposide,doxorubicin and cisplatin:a randomized assignment trial in gantric cancer显示文摘Kelsen D Atiq OT Sahz L 1992J Clin Oncol1992,10,4:1
16FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer 显示文摘Kelsen D Atiq OT Sahz L 1992J Clin Oncol1992,10,4:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费